
These are Hillman Value Fund's own holdings, not the firm's. Percentages are of the stock positions in its latest filing — the fund's cash and bonds are not included. An actively managed mutual fund for large-cap value stocks, this fund holds a concentrated basket of common shares in U.S. companies with durable competitive advantages—brands, pricing power, barriers to entry—that have temporarily fallen out of favor for short-term or non-recurring reasons. Only after a company clears a qualitative screen does a quantitative valuation process set what its shares are worth. The fund seeks long-term total return through income and capital gains rather than quick trades, and it does not press management to change, preferring to let a temporary problem work itself out while the underlying business stays sound. The fund opened to the public on December 29, 2000, and Mark Hillman has managed it since inception. It is the firm's registered mutual fund, the public counterpart to Hillman Capital Management's private accounts for foundations, endowments, and individual investors—offering a broader audience the same quality-value approach the manager has run since the mid-1990s. Hillman, a Tufts graduate who began his career as a financial consultant, leads the strategy himself and has drawn notice from Fortune, Bloomberg News, and Forbes.com for its results.
Hillman Value Fund opened new positions in UnitedHealth Group, West Pharmaceutical Services, UPS, Fiserv, and Akamai Technologies, while exiting AT&T, Advanced Micro Devices, Alphabet, The Options Clearing Corporation, West Pharmaceutical Services, and Microchip Technology. The fund trimmed GSK, Pfizer, Estee Lauder, DuPont, ASML, Kraft Heinz, Hershey, CVS Health, Biogen, Taiwan Semiconductor, Boeing, Microsoft, T. Rowe Price, Nucor, Nike, and US Bancorp, and substantially reduced Warner Bros. Discovery. It also added to Baxter International.
Full September 2025 recap →Stock Value
$101.01M
Positions
39
Top Position
GSK 3.0%
Top 10
28%